The goal of the institute for DiagNostic Accuracy (iDNA) is to reduce lung cancer mortality across the globe. By making screening and early detection of lung cancer a reality for many, we aim to reduce the incredible burden lung cancer has on the lives of patients and their families.
Worldwide four people die of lung cancer every minute. If lung cancer is detected at an early stage, the five-year survival rate is 56%. However, only 16% of lung cancer cases are diagnosed at such an early stage: more than 50% of people are diagnosed with lung cancer in a late stage, when the disease has already metastasized to other organs. Once the cancer has metastasized, the five-year survival rate is only 5%. Lung cancer is often detected too late for effective treatment, and more than half of the diagnosed patients die within a year.
The survival rates for lung cancer can only be increased when the cancer is detected at its earliest stages. The only scientifically proven method of achieving early stage detection is through screening with lose-dose CT scans. iDNA’s mission is to create a stage shift in the detection of lung cancer, as we aim to detect most newly diagnosed lung cancers in an early stage. In the NELSON study, 69% of all screen-detected detected cancers were found in stage I. iDNA uses the same protocol to ensure the efficient, cost-effective implementation of the highest quality cancer screening.
Early detection of lung cancer is key. Once detected, the proper and timely treatment of the cancer are essential for reducing mortality. iDNA facilitates academic institutions, as well as companies that focus their R&D on innovative diagnostic tooling and treatments that help lung cancer patients. Our global clinical trial infrastructure and in-house expertise provide our partners with unique opportunities to research or validate new technologies and drugs that localise and target cancers. This will positively impact lung cancer patients and doctors by expanding the available treatment options.
“Life changing early detection.” Up to now medical doctors were in most instances only able to extend the lives of people diagnosed with lung cancer. This is because lung cancer is almost always diagnosed in a late stage where survival rates are very low: nine out of ten persons that are diagnosed with a stage 4 lung cancer tumour will not be alive in five years. There have been big advancements in medication and treatment in the last decades, but due to the late stage diagnosis, these advancements were mainly live-extending and not live-saving. Recently, the results of the NELSON trial were published in the New England Journal of Medicine, showing low-dose CT-scans could detect lung cancer in an early stage and thereby reduce lung cancer mortality by 24% in males in a high-risk population (for the abstract, click on the image to the right). Therefore, the institute for DiagNostic Accuracy (iDNA) wants to accelerate high quality implementation and make lung cancer screening accessible for those who benefit.
Besides lung cancer screening, we have recently also engaged in helping in the fight against the COVID-19 pandemic. Check out our news item below or the article to the far right.
AGILEDxRx Conference Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment The first AGILEDxRx Conference will be hosted in Madrid, Spain from Thursday, May 9 to…
This week, the Antoni van Leeuwenhoek (AVL) Dutch Cancer Institute will officially start as the first Dutch center with a study on personalized lung cancer screening. After an earlier pilot…
Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy…
Start of the 4-In-The-Lung-Run trial in the Netherlands We are honored to be part of the European H2020 4-In-The-Lung-Run (4ITLR) Lung Cancer Screening trial with Dutch (ErasmusMC, Dutch Cancer…
OUR COLLABORATIONS AND SOLUTIONS
When you visit our website, it may store information through your browser from specific services, usually in the form of cookies. Here you can change your Privacy preferences. It is worth noting that blocking some types of cookies may impact your experience on our website and the services we are able to offer.
